Aktuelle Publikationen der GBG
Die zeitnahe Veröffentlichung der Studienergebnisse ist ein wichtiger Bestandteil einer Studie. Denn nur durch die Kommunikation der Ergebnisse können Therapieoptimierungen realisiert werden. Die GBG Forschungs GmbH ist für die Veröffentlichung sämtlicher Studien, unabhängig von ihren Ergebnissen, verantwortlich. Damit unterstreichen wir den akademisch-wissenschaftlichen Charakter unseres Forschungsinstituts.
Autoren dieser Fachpublikationen sind der Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme, der hauptverantwortliche Statistiker und Wissenschaftler der GBG Forschungs GmbH.
Unsere Publikationen erscheinen unter anderem in folgenden Fachzeitschriften: Journal of Clinical Oncology, Lancet, Journal of the National Cancer Institute, Annals of Oncology, European Journal of Cancer, Breast Cancer Research and Treatment.
Um maximale Transparenz bei der Vergabe der Ko-Autorenschaft zu gewährleisten, haben wir interne GBG Richtlinien entwickelt: SOP for authorship. Details unter: Rules for authorship GBG
Originalarbeiten 2013
Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S: Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2013 May 9. [Epub ahead of print]
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S: Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study. J Clin Oncol. 2013 Apr 22. [Epub ahead of print]
Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, Brase JC, Solbach C, Mehta K, Fasching PA, Sinn BV, Engels K, Reinisch M, Hansmann ML, Tesch H, von Minckwitz G, Untch M: HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res. 15(1):R11, 2013
Kongressbeiträge 2013
St. Gallen Congress
Untch M, Loibl S, Jackisch C, Wiebringhaus H, Forstbauer H, Wachsmann G, Zofia Maczynska, Valentina Nekljudova, Gunter von Minckwitz, Volker Möbus: Safety of 150mg/m²nab-paclitaxel weekly either as weekly or as 300mg/m² biweekly regimen. Poster presentation (Poster # 249) at St. Gallen Congress 2013
AACR
von Minckwitz G, Mamouhdian-Dekordi C, Loibl S, Blohmer J-U, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Mehta K, Untch M, Jackisch C: Response characteristics and overall survival of 781 patients with triple-negative breast cancer – a meta-analysis on 7 German neoadjuvant studies. Poster presentation (Poster # 1195) AACR in Washington, 2013
Loibl S, Denkert C, Loi S, Andre F, Schneeweiss A, Blohmer J, Jackisch C, Gade S, Fasching P, Schem C, Sotiriou C, Untch M, von Minckwitz G: PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Poster presentation (Poster # 1220) at AACR in Washington, 2013
Originalarbeiten 2012
Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Van Calsteren K, Linn SC, Schlehe B, Gziri MM, Westenend PJ, Müller V, Heyns L, Rack B, Van Calster B, Harbeck N, Lenhard M, Halaska MJ, Kaufmann M, Nekljudova V, Amant F: Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 13(9):887-96, 2012
Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A; on behalf of the AGO and GINECO study group: The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 23(10):2605-2612, 2012
Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching PA, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V: Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer. 107(6):956-60, 2012
Ditsch N, Vodermaier A, Hinke A, Burghardt S, Lenhard M, Löhrs B, Toth B, VON Koch F, Kahlert S, Bauerfeind I, Konecny GE, Loibl S, von Minckwitz G, Untch M: Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer. Anticancer Res. 32(8):3539-45, 2012
Massey Skatulla L, Loibl S, Schauf B, Müller T: Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature. Arch Gynecol Obstet. 286(1):89-92, 2012
Loibl S, Han SN, Amant F: Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel 7(3):204-209, 2012
Denkert C, Bucher E, Hilvo M, Salek R, Orešč M, Griffin J, Brockmöller S, Klauschen F, Loibl S, Barupal DK, Budczies J, Iljin K, Nekljudova V, Fiehn O: Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 4(4):37, 2012
von Minckwitz G, Untch M, Blohmer J-U, Costa S-D, Eidtmann H, Fasching P.A, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny G, Denkert C, Nekljudova V, Mehta K, Loibl S for the GBG and AGO-B study groups: Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30(15):1796-804, 2012
Azim HA Jr, Metzger-Filho O, de Azambuja E, Loibl S, Focant F, Gresko E, Arfi M, Piccart-Gebhart M: Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 133(1):387-91, 2012
Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R: Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13(4):e148-60, 2012
von Minckwitz G, Nekljudova V, Loibl S: What can be learned from trials running short of patients or events? J Clin Oncol. 30(9):901-3, 2012
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 366(4):299-309, 2012
Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Vandenberg T: Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol. 81(2):136-50, 2012
Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C: Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer - link to patient survival, hormone receptor status and metabolic profiling. J Proteome Res. 11(2):850-60, 2012
Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G; for the German Breast Group (GBG); the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 13(2):135-144, 2012
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast ancer. N Engl J Med. 366(4):299-309, 2012
Kongressbeiträge 2012
SABCS 2012
Martin M, Loibl S, von Minckwitz G, Morales S, Crespo C, Anton A, Guerrero A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JA, Gil M,Ramos M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba J R: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - First efficacy results from the LEA study. Cancer Res 72 (24 Suppl.): 91s, 2012
Kuehn T, Bauerfeind IGP, Fehm T, Fleige B, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schrenk P, Staebler A, Untch M: Sentinel lymph node biopsy before or after neoadjuvant chemotherapy - final results from the prospective German, multiinstitutional SENTINA-trial. Cancer Res 72 (24 Suppl.): 95s, 2012
Loibl S, Jackisch C, Gade S, Untch M, Paepke S, Kuemmel S, Schneeweiss A, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B,Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Nekljudova V, Mehta K, von Minckwitz G: Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res 72 (24 Suppl.): 96s, 2012
Denkert C. Blohmer JU, Müller BM, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Budczies J, Erbstößer E, Loibl S, von Minckwitz G: Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial. Cancer Res 72 (24 Suppl.): 102s, 2012
Klauschen F, Wienert S, Blohmer J-U, Mueller BM, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Erbstoesser E, Loibl S, Denkert C, von Minckwitz G: Automated computational Ki67 scoring in the GeparTrio breast cancer study cohort. Cancer Res 72 (24 Suppl.): 33s, 2012
von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer J-U, Costa S-D, Jackisch C, Paepke S, Schneeweiss A, Kuemmel S, Denkert C, Mehta K, Untch M: Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Res 72 (24 Suppl.): 15s, 2012
Untch M, Prinzler J, Fasching P, Müller BM, Gade S, Meinhold-Heerlein I, Huober J, Karn T, Liedtke C, Loibl S, Müller V, Rack B, Schem C, Darb-Esfahani S, von Minckwitz G, Denkert C: Expression of SPARC in human breast cancer and its predictive value in the GeparTrio neoadjuvant trial. Cancer Res 72 (24 Suppl.): 36s, 2012
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring A, Giermek J, Fehm T, Wildiers H, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Lenhard M, Witteveen PO, Kaufmann M, Van Calster B, Loibl S: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial. Cancer Res 72 (24 Suppl.): 71s, 2012
Hanusch C, Schneeweiss A, Untch M, Paepke S, Kuemmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Loibl S, Nekljudova V, von Minckwitz G: Dual blockade with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70. Cancer Res 72 (24 Suppl.): 18s, 2012
Linder M, von Minckwitz G, Kamischke A, Rudolwski C, Eggemann H, Nekljudova V, Loibl S: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (GBG-54 MALE). Cancer Res 72 (24 Suppl.): 43s, 2012
Untch M, Jackisch C, Blohmer J-U, Costa S-D, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Kuemmel S, Schneeweiss A, Paepke S, Loibl S, Nekljudova V, von Minckwitz G: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) GBG 69. Cancer Res 72 (24 Suppl.): 67s, 2012
Thomssen C, Kantelhardt EJ, Meisner C, Vetter M, Schmidt M, Martin P-M, Veyret C, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jaenicke F, von Minckwitz G, Harbeck N: First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. Cancer Res 72 (24 Suppl.): 15s, 2012
ESMO 2012
Ataseven B, Blohmer J.U, Denkert C BeGerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G for the GBG and AGO-B Study Groups: Impact of multifocal or multicentric disease on surgical, locoregional, and distant survival after neoadjuvant chemotherapy in 3562 breast cancer patients. Annals of Oncology Volume 23 (Supplement 9), 117, 2012
Loibl S, De la Haba J, von Minckwitz G, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin M: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - Safety Analysis LEA study. Annals of Oncology Volume 23 (Supplement 9), 118, 2012
ASCO 2012
von Minckwitz G, Mueller B, Blohmer J.U, Kaufmann M, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Ruediger T, Erbstoesser E, Loibl S, Denkert C: Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. J Clin Oncol 30, (suppl; abstr 1023), 2012Sinn B.V, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Belau A, Kronenwett R, Holzhausen H.J, Mehta K, Loibl S: Mucin-1 protein and mRNA expression in breast cancer: Predictive value for therapy response and survival after neoadjuvant chemotherapy. J Clin Oncol 30, (suppl; abstr 522), 2012
EBCC 2012
Harbeck N, Maass N, Mundhenke C, Lerchenmüller C, Barinoff J, Etti J, Aktas B, Nekljudova V, von Minckwitz, Loibl S: Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study. European Journal of Cancer Vol. 48, Supplement 1, S43, 2012
Loibl S, von Minckwitz G, Kaufmann M: Adjuvant hormone therapy following primary therapy for endometrial cancer Preview. European Journal of Cancer Vol. 38, Supplement 6, 41-43, 2012
von Minckwitz G, Steffen J, Wiest W, Thomssen C, Augustin D, Conrad B, Wesenberg B, Wittenberg M, Loibl S: Patient Self-reported Outcome for Long-term Follow up of Early Breast Cancer Trials. European Journal of Cancer Vol. 48, Supplement 1, S52, 2012
Loibl S, Gerber B: Managing adverse effects of treatment – Fertility. European Journal of Cancer Vol. 48, Supplement 1, S101, 2012
Loibl S: Breast Cancer in the Young. European Journal of Cancer Vol. 48, Supplement 1, S45, 2012
Originalarbeiten 2011
Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching P.A. Barinoff J, Holms F, Thomssen C, Zahm D-M, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G, for the German Breast Group and AGO-B Study Group: Re-challenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy. Breast Care 6:279-283, 2011
Denkert C, Sinn BV, Issa Y, Maria Müller B, Maisch A, Untch M, von Minckwitz G, Loibl S: Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care (Basel) 6(4):265-272, 2011
Loibl S, Doering G, Müller L, Grote-Metke A, Müller R, Tomé O, Wiest W, Maisch A, Nekljudova V, von Minckwitz G: Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial. Breast Care 6:457-461, 2011
Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN: Bevacizumab Treatment for Advanced Breast Cancer. Oncologist. 2011 Oct 5. [Epub ahead of print]
Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C: Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 130(2):477-87, 2011
von Minckwitz G, Loibl S, Jackisch C, Paepke S, Nestle-Kraemling C, Lux MP, Maass N, Schmutzler R, du Bois A, Wallwiener D, Vescia S, Budischewski K, Kaufmann M: The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiol Biomarkers Prev. 20(10):2141-9, 2011
Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 29(25):3351-7, 2011
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; On behalf of the GBG 26/BIG 03-05 study group and participating investigators: Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 47(15):2273-2281, 2011
Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, Lück HJ, Wagner U: Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group. Gynecol Oncol. 123(1):27-32, 2011
Denkert C, Darb-Esfahani S, Loibl S, Anagnostopoulos I, Jöhrens K: Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Semin Immunopathol. 33(4):341-51, 2011
von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C: Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2011 Jun 12. [Epub ahead of print]
Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer H, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S on behalf of the German Breast Group Investigators: Effect of LHRH agonists on ovarian function after modern-type adjuvant breast cancer chemotherapy : The GBG 37 "ZORO" study. J Clin Oncol. 29(17):2334-41, 2011
von Minckwitz G, Müller M.B, Loibl S, Budczies J Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C for GBG investigators: Cytoplasmic Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. J Clin Oncol. 29(16):2150-7, 2011
Loibl S, Skacel T, Nekljudova V, Lück HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G: Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer– a pooled analysis. BMC Cancer. 12;11:131, 2011
Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyotylainen T, Kallioniemi O, Iljin K, Oresic M: Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 71(9):3236-3245, 2011
Untch M, Fasching P.A, Konecny G, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Loibl S, von Minckwitz G on behalf of the AGO PREPARE investigators: PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin / cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer – results at the time of surgery. Ann Oncol. 22(9):1988-98, 2011
Untch M, von Minckwitz G, Konecny G, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann M.W, Salat C, Harbeck N, Müller M, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Loibl S, Fasching P.A, on behalf of the AGO PREPARE investigators: PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus standard dose and schedule of epirubicin / cyclophosphamide followed by paclitaxel without CMF ± darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann Oncol. 22(9):1999-2006, 2011
Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G: Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat. 126(1):109-17, 2011
Loibl S, Lintermans A, Dieudonné AS, Neven P: Management of menopausal symptoms in breast cancer patients. Maturitas. 68(2):148-54, 2011
von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P: Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 125(1):145-56, 2011
Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; On behalf of the GBG/AGO/NOGGO study groups: Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 19(11):1789-95, 2011
Letters to the editor 2011
Loibl S, Gerber B: Gonadotropin-releasing hormone analogue for premenopausal women with breast cancer. JAMA. 306(16):1760-1, 2011
Loib S, von Minckwitz G, Gerber B: Reply to L. Del Mastro and Z. Blumenfeld. J Clin Oncol vol. 29 no. 24: 3341-2, 2011
Denkert C, Loibl S, Müller B, von Minckwitz G: Reply to L Ozretić, et al. J Clin Oncol vol 20, Published online 2011
Kongressbeiträge 2011
SABCS 2011
de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A, Coleman R: Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. Cancer Res 71(24 Suppl.): 96s, 2011Möbus V, Diel IJ, Elling D, Harbeck N, Jackisch C, Thomssen C, Untch M, Conrad B, Schneeweiss A, Kreienberg R, Huober J, Müller V, Lück HJ, Bauerfeind I, Loibl S, Nekljudova V, von Minckwitz G for the GBG/AGO study groups: Gain study: A phase III trial to compare ETC vs. EC-TX and Ibandronate vs. observation in patients with node-positive primary breast cancer – 1st interim EFFICACY analysis. Cancer Res 71(24 Suppl.): 100s, 2011
von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Michael Zahm D, Mehta K, Loibl S: Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients – Results of the GeparTrio trial. Cancer Res 71(24 Suppl.): 103s, 2011
Huober J, Hanusch C, Fasching P, Rezai M, Eidtmann H, Kittel K, Schwedler K, Tesch H, Höß C, Mau C, Khandan F, Krabisch P, Loibl S, Nekljudova V, Untch M von Minckwitz G for the GBG and AGO-B study groups: Neoadjuvant CHEMOTHERAPY of Paclitaxel with or Without Rad001 Results of the NON-Responder Part of The GEPARQUINTO study (GBG 44). Cancer Res 71(24 Suppl.): 105s, 2011
Loibl S, von Minckwitz G, Blohmer JU,Costa SD, Eidtmann H, Fasching P, Gerber B, Hilfrich J, HuoberJ , Jackisch C, Kaufmann M, Konecny G, Denkert C, Nekljudova V, Mehta K, Untch M for the GBG and AGO-B study groups: pCR as surrogate in HER2-positive patients treated with trastuzumab - taking into account anti-HER2 treatment. Cancer Res 71(24 Suppl.): 111s, 2011
von Minckwitz G, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M for the GBG and AGO-B study groups: Local recurrence risk after neoadjuvant chemotherapy. Pooled analysis on 5477 breast cancer patients. Cancer Res 71(24 Suppl.): 142s, 2011
Brase JC, Gehrmann MC, Petry C, Weber KE, Schmidt M, Kölbl H, Brauch H, Schwab M, Müller V, Jänicke F, Rody A, Kaufmann M, Filipits M, Gnant M, Denkert C, Loibl S, von Minckwitz G, Kronenwett R: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer. Cancer Res 71(24 Suppl.): 187s, 2011
Eidtmann H, Kittel K, Rezai M, Tesch H, Ulmer HU, Stirnberg S, Belau A, Mau C, Stickeler E, Schrader I, Fasching P, Salat C, Abdallah A, Holms F, Schwedler K, Nekljudova V, Loibl L, von Minckwitz G: Surgical complications from the GeparQuinto trial of patients receiving preoperative Bevacizumab. Cancer Res 71(24 Suppl.): 237s, 2011
Coleman R, De Boer R, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A, Bundred N: Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole: Exploratory Analyses from the ZO-FAST Trial. Cancer Res 71(24 Suppl.): 325s, 2011
Witzel ID, Loibl S, von Minckwitz G, Abdallah A, Kühn T, Overkamp F, Fehm T, Schrader I, Uleer C, Kohls A, Stirnberg S, zu Eulenburg C, Untch M, Müller V: Predictive Value of HER2 Serum Levels in Patients Treated with Lapatinib or Trastuzumab – A Translational Project in the Neoadjuvant "Geparquinto" Trial. Cancer Res 71(24 Suppl.): 454s, 2011
von Minckwitz G, Baselga J, Bradbury I, de Azambuja E, Scullion MJ, Ross G, Saini KS, Piccart-Gebhart M: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4-11/BO25126/TOC4939g). Cancer Res 71(24 Suppl.): 602s, 2011
von Minckwitz G, Cortés J, Gligorov J, Marschner NW, Puglisi F, Vrdoljak E, Duenne A-A, Zielinski C: TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC). Cancer Res 71(24 Suppl.): 621s, 2011
de la Haba HR, von Minckwitz G, Martín M, Morales S, Crespo C, Guerrero A, Antón A, Gil M, Muñoz M, Carrasco E, Rodríguez C, Porras I, Aktas B, Schoenegg W, Tio J, Mehta K, Loibl S, on behalf of GEICAM and GBG: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the LEA study. Cancer Res 71(24 Suppl.): 625s, 2011
ASCO Breast 2011
von Minckwitz G, Darb-Esfahani S, Loibl S, Tesch H, Huober J, Solbach C, Holms F, Eidtmann H, Diedrich K, Just M, Clemens M, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C: Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40). ASCO Breast 2011 (Poster)
Senologie 2011
Maisch A, Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching P.A, Barinoff J, Holms F, Thomssen C, Zahm D.M, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G: Wiedereinsatz von Taxanen beim rezidivierten Brustkrebs von Patientinnen, die mit einer (neo-) adjuvanten Taxan-haltigen Chemotherapie behandelt wurden. Senologie 2011 (Poster)
ASCO 2011
Gerber B, Eidtmann H, Rezai M, Fasching P. A, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C. A, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer J.U, Huober J.B, Hauschild M, Loibl S, Nekljudova V, Untch M, von Minckwitz G, GBG/AGO study groups: Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 29: 2011 (suppl; abstr 1006)
Wenners A. S, Mehta K, Loibl S, Park H, Arnold N, Hamann S, Weimer J, Ataseven B, Schem C, Khandan F, Thomssen C, Jonat W, Holzhausen H, von Minckwitz G, Denkert C, Bauer M: Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 595)
Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Hanker L. C, Sänger N, Holtrich U, Kaufmann M, Darb-Esfahani S, Nekljudova V, von Minckwitz G: Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 615)
Heitz F, Sinn B, Loibl S, du Bois A, Jackisch C, Kuemmel S, Denkert C, Barinoff J, Mehta K, von Minckwitz G, on behalf the GeparTrio trialists: Effect of estrogen receptor beta expression (ERße) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. J Clin Oncol 29: 2011 (suppl; abstr 1069)
Budczies J, Denkert C, Mueller B, Brockmoeller S.F, Dietel M, Radke C, Loibl S, von Minckwitz G, Griffin J.L, Oresic M, Wohlgemut G, Fiehn O: Separation of breast cancer from normal tissues using GC-MS-based metabolite profiling. J Clin Oncol 29: 2011 (suppl; abstr 10514)
Denkert C, Kronenwett R, Loibl S, Nekljudova N, Darb-Esfahani S, Gerber B, Sinn B, Petry C, Bauerfeind I, Budczies J, Rezai M, Dietel M, Schrader I, Kunz G, von Minckwitz G, GBG and AGO-B study groups: RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy. J Clin Oncol 29: 2011 (suppl; abstr 10526)
Originalarbeiten 2010
Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; On behalf of the GBG/AGO/NOGGO study groups: Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 2010 Oct 16. [Epub ahead of print]
Kaufmann M, Maass N, Costa SD, Schneeweiß A, Loibl S, Sütterlin MW, Schrader I, Gerber B, Bauer W, Wiest W, Tomé O, Distelrath A, Hagen V, Kleine-Tebbe A, Ruckhaeberle E, Mehta K, von Minckwitz G; for the GBG-39 trialists: First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. Eur J Cancer. 46(18):3184-3191, 2010
Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 124(1):133-40, 2010
von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M; for the German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie--Brust investigators: Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 22(2):301-306, 2010
Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, Hauschild M, Lantzsch T, Tesch H, Latos K, Just M, Hilfrich J, Barinoff J, Eulenburg CZ, Roller M, Untch M, Müller V: Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat. 123(2):437-45, 2010
Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M: Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study. J Clin Oncol. 28(17):2874-80, 2010
Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 21(11):2188-94, 2010
Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K: Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 16(9):2634-45, 2010
von Minckwitz G, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch K, Kühn T, du Bois A, Blohmer J.U, Thomssen C, Costa S.D, Jackisch C, Kaufmann M, Mehta K, Untch M: Capecitabine in Addition to Anthracycline / Taxane-based Neoadjuvant Treatment in Patients with Primary Breast Cancer: The Phase III GeparQuattro Study. J Clin Oncol. 28(12):2015-23, 2010
Untch M, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer J.U, Thomssen C, Costa S.D, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G for the German Breast Group and AGO Breast Group: Neoadjuvant Treatment with Trastuzumab in HER2-positive Breast Cancer: Results from GeparQuatro Study. J Clin Oncol 28(12):2024-31, 2010
Denkert C, Loibl S, Noske A, Roller M, Müller B, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G: Tumor-associated Lymphocytes as an Independent Predictor of Response to Neo-adjuvant Chemotherapy in Breast Cancer. J Clin Oncol 28(1):105-13, 2010
Costa S.D, Loibl S, Kaufmann M, Zahm D.M, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J.U, Eiermann W, Weiss E, Tesch H, Gerber B, Baumann K.H, Thomssen C, Breitbach G.P, Ibishi S, Jackisch C, Mehta K, von Minckwitz g, for the German Breast Group: Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: A secondary analysis of the GEPARTRIO trial data. J Clin Oncol 28(1):83-91, 2010
Eiermann W, Graf E, Ataseven B, Conrad B, Hilfrich J, Massinger-Biebl H, Vescia S, Loibl S, von Minckwitz G, Schumacher M, Kaufmann M; for the German Adjuvant Breast Cancer Group: Dose-intensifed epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph npdes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer Group. Eur J Cancer 46(1):84-94, 2010
Kongressbeiträge 2010
SABCS 2010
von Minckwitz G, Eidtmann H, Rezai M, Fasching P,Tesch H, Costa SD, Schrader I, Kittel K., Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Loibl S, Nekljudova V, Untch M for the GBG/AGO study groups: Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44). Cancer Res 2010, Vol. 70 (Nr. 24 Suppl): Abstract # S4-6, Page: 86s
Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching P, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G for the GBG/AGO study group: Lapatinib vs Trastuzumab in Combination with Neoadjuvant Anthracycline−Taxane−Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO STUDY (GBG 44). Cancer Res 2010, Vol. 70 (Nr. 24 Suppl): Abstract # S3-1, Page: 81s
Loibl S, Amant F, Kaufmann M, Ring A, Han S, Giermek J, Fehm T, Bontenbal M, Heinrigs M, Lenhard M, Scherr I, Mehta K, von Minckwitz G: 1313 patients with breast cancer during pregnancy – results from a prospective and retrospective registry (GBG-20/BIG02-03). Cancer Res 2010, Vol. 70 (Nr. 24 Suppl): Abstract # S6-2, Page: 91s
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhencke C, Cufer T, Maartense E7, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maas N, Zielinski C, Anderson M, Stein R, Nekljudova V, Loibl S on behalf of the GBG 26 / BIG 03-05 Study group: Final overall survival analysis of the TBP phase III study (GBG 26 / BIG 3-05): capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment. Cancer Res 2010, Vol. 70 (Nr. 24 Suppl): Abstract #P6−14−05, Page 459s
ASCO 2010
Kühn T, Bauerfeind I, Fehm T, Fleige B, Helms G, Liedtke C, Mai M, von Minckwitz G, Staebler A, Untch M: Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial. J Clin Oncol 28(15S):10s, 2010 (suppl; abstr TPS 114), ASCO 2010
Thomssen C, Kantelhardt E.J, Plueckhahn K, Veyret C, Augustin D, Hanf V, Paepke D, Meisner C, von Minckwitz G, Harbeck N, On behalf of the NNBC-3 Europe study group: Report of toxicities from the multicentre, randomised NNBC 3-europe trial: 6xFEC versus 3xFEC – 3xDoc for high-risk node-negative breast cancer patients. J Clin Oncol 28(15s):80s, 2010 (suppl; abstr 554)
Darb-Esfahani S, von Minckwitz G, Gehrmann M, Kronenwett R, Denkert C, Budczies J, Rody A, Kuemmel S: Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer. J Clin Oncol 28(15s):726s, 2010 (suppl; abstr 10514), ASCO 2010
E. J. Kantelhardt, C. Thomssen, M. Vetter, C. Meisner, M. Schmidt, P. Martin, F. Sweep, G. Von Minckwitz, M. Schmitt, N. Harbeck, On behalf of the NNBC 3-Europe study group.; Molecular types and prognostic markers uPA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial. J Clin Oncol 28(15s):732s, 2010 (suppl; abstr 10539), ASCO 2010
EBCC 2010
Witzel I, Müller V, Loibl S, Fehm T, von Minckwitz G, Eidtmann H, Conrad U, Roller M, zu Eulenburg C, Untch M: Monitoring serum HER2 levels in the neoadjuvant „Geparquattro“ trial-a decrease predicts pathological complete remission. Eur J Cancer 8(3):61, 2010, Poster discussion / Abstract # 12
von Minckwitz G, Müller B, Loibl S, Blohmer J.U, du Bois A, Huober J, Kandolf R, Budczies J, Denkert C: PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy. Eur J Cancer 8(3):188, 2010, Proffered paper oral / Abstract # 443
DKK 2010
Vetter M, Thomssen C, kantelhardt E, Geurts-Moespot A, Schmidt M, Veyret C, Meisner C, von Minckwitz G, Hanf V, Martin P, Schmitt M, Sweep F, Harbeck N: Die Bestimmung der prognostischen Faktoern uPA und PAI 1 zur Risikoevaluation beim nodalnegativen Mammakarzinom-Erfahrungen der NNBC3-Europe Studie. Internal Journal for Cancer Research and Treatment 33, Supplement 2, Page 25, Abstrct # FV110, DKK 2010, Berlin
DGP 2010
Müller B, Loibl S, Darb Esfahani S, Solbach C, Budczis J, Lichtenegger W, Dietel M, Delling G, Denkert C, von Minckwitz G: PARP expression in primary operable breast cancer –translational research in GeparTrio. 94. Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Mai 2010
Klauschen F, Loibl S, Darb-Esfahani S, Stenzinger A, Linde M, Dietel M, von Minckwitz G, Denkert C: Automated quantitative analysis of Her2 expression in immunohistochemical data in a neoadjuvant breast cancer study. 94. Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Mai 2010
Müller B, von Minckwitz G, Darb-Esfahani S, Eierman W, Kaufman M, Roller M, 3, Denkert C, Loibl S: Androgenrezeptor-Expression in hormonrezeptor negativen / Her2- negativen Mammakarzinomen der GeparTrio Studie. 94. Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Mai 2010
Darb-Esfahani S, Loibl S, Müller B, Schwedler k, Denkert C, Kantelhardt E, Budczies J, Ataseven B, Dietel M, von Minckwitz G: Biologische Tumortypen des Mammakarzinoms: Prädiktiver und prognostischer Wert bei Patientinnen mit neoadjuvanter Anthracyclin- und Taxan-haltiger Chemotherapie. 94. Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Mai 2010
Originalarbeiten 2009
Costa S.D, Loibl S, Kaufmann M, Zahm D.M, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J.U, Eiermann W, Weiss E, Tesch H, Gerber B, Baumann K.H, Thomssen C, Breitbach G.P, Ibishi S, Jackisch C, Mehta K, von Minckwitz g, for the German Breast Group: Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: A secondary analysis of the GEPARTRIO trial data. J Clin Oncol 28(1):83-91, 2009
Engels K, du Bois A, Harter P, Fisseler-Eckhoff A, Kommoss F, Stauber R, Kaufmann M, Nekljudova V, Loibl S: VEGF-A and i-NOS Expression are Prognostic Factors in Serous Epithelial Ovarian Carcinomas after Complete Surgical Resection. J. Clin. Pathol 62(5):448-54, 2009
Darb-Esfahani S, Loibl S, Müller B.M, Roller M, Denkert C, Komor M, Schlüns K, Blohmer J.U, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 11(5):R69, 2009
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. Cancer Chemother Pharmacol 63(5):953-8, 2009
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh F.E, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann K. H, Clemens M.R, Duerr R, Uleer C, Andersson M, Stein R.C, Nekljudova V, Loibl S: Trastuzumab beyond progression in humen epidermal growth factor receptor 2-positive advance breast cancer: a german breast group 26/Breast international group 03-05 study. J Clin Oncol 27(12):1999-2006, 2009
Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, Siggelkow W, Hengstler J.G, Elsaßer A, Gehrmann M, Lehr H.A, Koelbl H, von Minckwitz G, Harbeck N, Thomssen C: Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomised Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 20(2):258-64, 2009
Kongressbeiträge 2009 (Abstracts, Poster, Präsentationen)
St. Gallen
ICE study: Ibandronate with or without Capecitabine in Elderly Patients with Early Breast Cancer (Abstract)
ASCO
ESMO/ECCO
ZORO study: Präsentation: siehe ASCO
SABCS
Originalarbeiten 2008
Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kummel S: Clinical feasibility of (neo)adjuvant taxane based chemotherapy in elderly patients: an analysis of > 4,500 patients from four german randomized breast cancer trials. Breast Cancer Res 10(5):R77, 2008
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa C.D, Jackisch C, Loibl S, Mehta K, Kaufmann M: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100(8):542-51, 2008
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa S.D, Jackisch C, Loibl S, Mehta K, Kaufmann M: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100(8):552-62, 2008
von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa S.D, Jackisch C, Grasshoff S.T, Vescia S, Skacel T, Loibl S, Mehta K, Kaufmann M: Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19(2):292-8, 2008
von Minckwitz G, Sinn H.P, Raab G, Loibl S, Blohmer J.U, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa S.D, Caputo A, Kaufmann M: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10(2):R30, 2008
Engels K, Knauer S.K, Loibl S, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber R.H: NO signalling confers cytoprotectivity the surviving network in ovarian carcinomas. Cancer Res 68(13):5159-66, 2008
Abstracts 2008
von Minckwitz G, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J.U, Costa S.D, Loibl S, Volz D, Untch M: Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing hemotherapy. Cancer Res 2009, 69(Suppl.):(2). (SABCS 2008, Oral Presentation # 79)
Loibl S, Müller B, Roller M, Kronenwett R, Darb-Esfahani S, Komor M, von Toerne C, Wirtz R, von Minckwitz G, Denkert C on behalf of the German Breast Group: Local versus Central HER2 Immunohistochemistry Correlates with kinetic RT-PCR but Only Central Immunohistochemistry and RT-PCR predict Pathological Complete Response: Results from the Neoadjuvant Multicenter GeparTrio Trial. Cancer Res 2009, 69(Suppl.):(2). (SABCS 2008, Poster # 1070)
von Minckwitz G, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M for the German Breast Group and AGO Breast Group: Effect of trastuzumab on pathologic complete response rate of neoadjuvant EC-docetaxel treatment in HER2-overexpressing breast cancer: Results of the phase III GeparQuattro study. Breast Cancer Symposium, Proceeding Book 2008, Astract # 226, Page Nr. 198 (ASCO Breast 2008)
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – the RiTa trial. Breast Cancer Symposium, Proceeding Book 2008, Astract Nr. 178, Page Nr. 174 (ASCO Breast 2008)
von Minckwitz G, Zielinski C, Maartense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, De Jongh F.E, Kaufmann M, Loibl S: Capecitabine vs. Capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment – the TBP phase III study (GBG 26 / BIG 3-05). Ann Oncol 19(8):63, 2008 (ESMO 2008, Abstract # 133O)
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – the RiTa trial. Ann Oncol 19(8):69, 2008 (ESMO 2008, Abstract # 155P)
Untch M, Fasching P.A, Bauerfeind I, Conrad U, Camara O, Fett W, Kuzeder W, Lück H, Loibl S, von Minckwitz G: PREPARE trial. A randomized phase III trial comparing preoperative, dose dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin / cyclophosphamide followed by paclitaxel darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. J Clin Oncol 26(15S):10s, 2008 (ASCO 2008 Abstarct # 517)
von Minckwitz G, Zielinski C, Maartense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Kaufmann M, Loibl S: Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26 / BIG 3-05). J Clin Oncol 26(15S):47s, 2008 (ASCO 2008, Abstract # 1025)
Untch M, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, von Minckwitz G: Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophoshamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study "GeparQuatro". Eur J Cancer 6(7):47, 2008 (EBCC Berlin 2008)
Loibl S, Ring A, von Minckwitz A, Heinrigs M, Lenhard M, Amant F, Weiss C, Augustin D, Nekljudova V, Kaufmann M: Breast cancer during pregnancy – a prospective and retrospective registry (GBG-20/BIG02-03). Eur J Cancer 6(7):68, 2008 (EBCC Berlin 2008)
Vescia S, von Minckwitz G, Loibl S, Jackisch C, Paepke S, Nestle-Kremmling C, Lux M.P, Maass N, Schmutzler R, Kaufmann M: The Giss Trial: A pilot phase randomized prevention trial of screening plus goserelin plus ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer. Eur J Cancer 6(7):72, 2008 (EBCC 2008)
Loibl S: Young woman and fertility in breast cancer. Eur J Cancer 6(7):105, 2008 (EBCC Berlin 2008)
von Minckwitz G, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M: Capecitabine given concomitantly or in sequence with EC ---> docetaxel as neoadjuvant treatment for early breast cancer: GeparQuatro - a GBG/AGO intergroup study. Eur J Cancer 6(7):108, 2008 (EBCC Berlin 2008)
Loibl S, Murmann C, Schwedler K, Warm M, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – The RiTa trial. Internal Journal for Cancer Research and Treatment 31(1), 2008 (DKK Berlin 2008)
Originalarbeiten 2007
Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta K, Kaufmann M: Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol 18(4):689-93, 2007
Kaufmann M, Graf E, Jonat W, Eiermann W, Vescia S, Geberth M, Conrad B, Gademann G, Albert U.S, Loibl S, von Minckwitz G, Schumacher M: A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. Eur J Cancer 43(16):2351-8, 2007
Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhaberle E, von Minckwitz G, Loibl S, Holtrich U, Kaufmann: The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16(3):235-40, 2007
Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, allo-Danebrock R, Ruckhaberle E, Metzler D, Ahr A, Solbach C, Karn T, Kaufmann M: Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 13(4):1115-22, 2007
Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 16(1):86-93, 2007
Abstracts 2007
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Houber J, Costa S, Loibl S: Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from the GEPARTRIO study. J Clin Oncol 25(18S):13s, 2007 (ASCO 2007, # 542)
Loibl S, Schmidt M, Marquart, Houber J, Bischoff J, von Minckwitz G, Mehta K, Kaufmann M: Mitomycin C in combination with capecitabine (Mi-Cap) as chemotherapy in breast cancer with extensive liver metastases and impaired hepatic function: A non-randomized multicentre phase II. J Clin Oncol 25(18S):714s, 2007 (ASCO 2007, Nr. 19597)
Mueller V, Reithdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K: Prospective monitoring of circulating tumor cells in bresat cancer patients treated with primary systemic therapy-A translational project of the German Breast Group study GeparQuattro. J Clin Oncol 25(18S):735s, 2007 (ASCO 2007, Nr.21085)
Loibl S, Pfisterer J, Wimberger P, Kurzeder C, du Bois A, Sehouli J, Belau A, Burchardi N, Vergote I, Wagner U: Randomised, multicenter, 2-dose-level, open label, phase IIa study with the intraperitoneally infused trifunctional biospecific antibody catumaxomab (anti-EpCAM x anti CD3) to select the better dose level inplatinum refractory epithelial ovarian cancer patients. Eur J Cancer 5(4):312, 2008 (ECCO 2007, # 5005, Oral Presentation)
Reithdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K, Mueller V: Incidence and kinetics of circulating tumor cells in breast cancer patients treated with primary systemic therapy including trastuzumab for patients with HER2-positive tumors a translational project within the study Gepar Quattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.5025), Page Nr. S214
Rody A, Holtrich U, Gaetje R, Engels K, von Minckwitz G, Loibl S, Gehrmann M, Ruckhaberle E, Ahr A, Solbach C, Karn T, Kaufmann M: Breast cancer classication according to stem cell-like features and its relevance for systemic adjuvant treatment decision. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.3103), Page Nr. S161
Untch M, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, von Minckwitz G: Evaluating the efficacy and safety of trastuzumab given concomitantly to epirubicin/ cyclophosphamide docetaxelcapecitabine as neoadjuvant treatment of HER2 verexpressing primary breast cancer. First analysis of the GBG/AGO intergroup-study GeparQuattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.5053), Page nr. S224
von Minckwitz G, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M: Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study GeparQuattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.79), Page Nr. S21
von Minckwitz G, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Maartense E, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S: Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer the TBP study (GBG 26/BIG 3-05). Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.4056), Page Nr. S185
Loibl S, von Minckwitz G, Heinrigs M, Lenhard M, Amant F, Wolf I, Weiss C, Augustin D, Nekljudova V, Kaufmann M: Breast cancer during pregnancy – a prospective and retrospective registry (GBG-20/BIG02-03). ESGO 2007
von Minckwitz G, Blohmer J.U, Raab G, Steffen J, Kaufmann M, Loehr A, Gerber B, Heinrich G, Eidtmann H, Hilfrich J, Jackisch C, Costa S.D, Houber J, Bühler H, Loibl S: Prospective central assessment of HER-2 status by FISH is not a predictive factor for pathologic complete response (pCR) in 648 breast cancer patients treated preoperatively with an anthracycline / taxane based regimen in the multicenter GeparTrio trial. AACR 2007
Kontakt:
Fon: +49 6102 7480-418
Fax: +49 6102 7480-118
Diese E-Mail-Adresse ist gegen Spambots geschützt! Sie müssen JavaScript aktivieren, damit Sie sie sehen können.